Search

Dr. Craig Thompson, Dr. Peter Bach, Dr. Ushma Neill, and Dr. William Rosa were recognized for their professional, civic, and philanthropic achievements.

… Monday, July 12, 2021 Memorial Sloan Kettering is proud to announce that President & Chief Executive Officer Craig B. Thompson, MD , Director of the Center for Health Policy and Outcomes Peter B. Bach, MD, Vice President of Scientific Education & Training Ushma Neill, PhD , and Postdoctoral Research

The May 13 installment of “MSK Science Spotlight” will feature co-winner of The Society of Memorial Sloan Kettering Prize, Carl June, MD.

… Wednesday, May 13, 2020 The May 13 installment of “MSK Science Spotlight” will feature co-winner of The Society of Memorial Sloan Kettering Prize, Carl June, MD. Dr. June is Director of the Center for Cellular Immunotherapies and Professor, Department of Pathology and Laboratory Medicine, Perelman School

Learn how proton therapy can be an effective new treatment for leptomeningeal metastasis.

… Monday, June 6, 2022 Leptomeningeal metastasis (LM) is a serious condition in which cancer spreads to the fluid and tissues surrounding the brain and spinal cord. This complication can have devastating effects, causing pain, seizures, difficulty thinking, and a loss of muscle control. Treatment with

In honor of Women's History Month, meet the scientific hero who shook up cancer research with her unusual findings.

… Wednesday, March 13, 2019 Summary In honor of Women’s History Month, we’re remembering female scientists from MSK’s past who shook up cancer research. Read about Ora Rosen and  Mathilde Krim . In the 1950s, the idea that cancer might be caused by a virus was somewhat heretical. Most known viruses caused

In cancer care, firsts make a difference. At MSK, we are constantly improving how we help people with those important firsts. Dr. Selwyn Vickers writes about the latest developments at MSK and the encouraging evidence that we are making progress in our mission of ending cancer for life.

… Saturday, July 1, 2023 Dear MSK Community, In cancer care, firsts make a difference: The first tests that diagnosis the disease. The first choices about where to be treated. The first decisions about how to treat it. At Memorial Sloan Kettering Cancer Center (MSK), we are constantly improving how we

More than 30,000 oncology professionals from around the world will gather in Chicago from May 31 to June 4 for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. For more information and to set up interviews, email [email protected]. Follow the meeting live on Twitter using the hashtag #ASCO19 and follow MSK on Twitter at @sloan_kettering.

… Wednesday, May 29, 2019 More than 30,000 oncology professionals from around the world will gather in Chicago from May 31 to June 4 for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting. MSK scientists and physicians will take part in nearly 140 presentations from plenary sessions to

It’s rare to meet someone who makes you want to be a better person. Cristy and Alec Fraser are those people — they are inspiring in an extraordinary and life-changing way.

… Thursday, August 26, 2021 It’s rare to meet someone who makes you want to be a better person. Cristy and Alec Fraser are those people — they are inspiring in an extraordinary and life-changing way. On August 15, the Frasers were part of a segment on Good Morning America and then rode their bikes from

At the ASCO meeting in Chicago, MSK medical oncologist William Tap talked about disappointing results from a new sarcoma drug, which didn’t increase survival.

… Sunday, June 2, 2019 Summary At this year’s annual meeting of the American Society of Clinical Oncology (ASCO), MSK medical oncologist William Tap talked about disappointing results from olaratumab, a new sarcoma drug that wasn’t shown to increase survival in a recent study. At this year’s American Society

Memorial Sloan Kettering is one of only a few centers in the U.S. to employ liver-directed therapies – using hepatic arterial infusion (HAI) – in conjunction with a number of systemic agents.

… Wednesday, December 7, 2016 There is a real and significant need to improve clinical outcomes in patients with cholangiocarcinoma by building on first-line chemotherapy regimens and developing novel strategies for treatment in the second-line setting. Cholangiocarcinomas are rare malignancies that arise

Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest foundational and translational cancer research at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5 to 10 in San Diego.

… Wednesday, April 10, 2024 Memorial Sloan Kettering Cancer Center (MSK) experts presented findings from their latest foundational and translational cancer research at the American Association for Cancer Research (AACR) Annual Meeting 2024, held April 5 to 10 in San Diego. Highlights included discoveries